Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Jul;59(7):1700-1709.
doi: 10.1080/10428194.2017.1390230. Epub 2017 Oct 25.

Exploring the potential cost-effectiveness of precision medicine treatment strategies for diffuse large B-cell lymphoma

Qiushi Chen  1   2 , Ashley D Staton  3 , Turgay Ayer  4 , Daniel A Goldstein  3   5 , Jean L Koff  3 , Christopher R Flowers  3
Affiliations

Exploring the potential cost-effectiveness of precision medicine treatment strategies for diffuse large B-cell lymphoma

Qiushi Chen et al. Leuk Lymphoma. 2018 Jul.

Abstract

Activated B-cell-like (ABC) diffuse large B-cell lymphoma (DLBCL) is associated with worse survival after standard rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (RCHOP) chemoimmunotherapy compared to germinal center B-cell-like (GCB) subtype. Preliminary evidence suggests that benefits from novel agents may vary by subtype. Hypothesizing that treatment stratified by DLBCL subtype could be potentially cost-effective, we developed micro-simulation models to compare three first-line treatment strategies: (1) standard RCHOP for all patients (2) subtype testing followed by RCHOP for GCB and novel treatment for ABC DLBCL, and (3) novel treatment for all patients. Based on phase 2 evidence, we used lenalidomide + RCHOP as a surrogate novel treatment. The subtype-based approach showed a favorable incremental cost-effectiveness ratio of $15,015/quality-adjusted life year compared with RCHOP. Although our exploratory analyses demonstrated a wide range of conditions where subtype-based treatment remained cost-effective, data from phase 3 trials are needed to validate our models' findings and draw definitive conclusions.

Keywords: ABC DLBCL; Lymphoma; cost-effectiveness; diffuse large B-cell lymphoma; subtype testing.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Subtype-based treatment strategy allows misclassification of germinal center B-cell-like (GCB)/activated B-cell-like (ABC) subtype due to imperfect testing by immunohistochemistry
Treatment selection is guided by the subtype identified by the test, whereas survival is determined by the true subtype for a given treatment.
Figure 2
Figure 2. Cost-effectiveness acceptability curves at various survival benefit levels for germinal center B-cell-like (GCB) and activated B-cell-like (ABC) subtypes
Subtype-based treatment is based on gene expression profiling (GEP) assay. (A) Minimal survival improvement for both subtypes by novel treatment, (B) modest survival improvement only for ABC subtype by novel treatment, (C) modest survival improvement for both subtypes by novel treatment.
See this image and copyright information in PMC

Comment in

References

    1. Teras LR, DeSantis CE, Cerhan JR, Morton LM, Jemal A, Flowers CR. 2016 US lymphoid malignancy statistics by World Health Organization subtypes. CA. J Clin. 2016 - PubMed
    1. Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000;403:503–511. - PubMed
    1. Choi WW, Weisenburger DD, Greiner TC, et al. A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy. Clin Cancer Res. 2009;15:5494–5502. - PMC - PubMed
    1. Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004;103:275–282. - PubMed
    1. Lenz G, Wright G, Dave S, et al. Gene expression signatures predict survival in diffuse large B cell lymphoma following rituximab and CHOP-like chemotherapy. Annals of Oncology. 2008;19:93–93.

Publication types

MeSH terms

LinkOut - more resources